# Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis

> **NCT05722691** · PHASE3 · COMPLETED · sponsor: **Promomed, LLC** · enrollment: 800 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Double-Stranded RNA sodium salt
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05722691
- **Lead sponsor:** Promomed, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-09
- **Primary completion:** 2022-11-22
- **Final completion:** 2023-01-17
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05722691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05722691, "Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05722691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*